Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9823-9830

  Koh, Young Wha ^a   Lee, Hee Jin ^b   Ahn, Jin Hee ^b   Lee, Jong Won ^b   Gong, Gyungyub ^b  

^a Ajou University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Breast cancer; Estrogen receptor; HER2 receptor; Neoadjuvant chemotherapy; Neutrophil lymphocyte ratio; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPHILS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922391558     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2282-5     Document Type: Article

References (43)

1. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-9.
2. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351-7.
3. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47:2084-90.
4. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005;23: 7098-104.
5. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-9.
6. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796-804.
7. Aaltomaa S, Lipponen P, EskelinenM, Kosma VM,Marin S, Alhava E, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992;28A:859-64.
8. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating cd8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949-55.
9. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288-95.
10. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010;184:873-8.
11. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:425-8.
12. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on cancer stage IV melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007;25: 1562-9.
13. Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol. 2012;138:846-54.
14. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19:217-24.
15. Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B, et al. Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013;20:013-3136.
16. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16:55-9.
17. Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol. 2014;18:18.
18. Kuang DM, Zhao Q,Wu Y, Peng C,Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54:948-55.
19. Scapini P, Morini M, Tecchio C, Minghelli S, Di Carlo E, Tanghetti E, et al. Cxcl1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-a. J Immunol. 2004;172:5034-40.
20. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, Ottonello L, et al. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol. 2011;89:721-7.
21. MunderM, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, et al. Suppression of t-cell functions by human granulocyte arginase. Blood. 2006;108:1627-34.
22. Schmielau J, Finn OJ. Activated granulocytes and granulocytederived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001;61:4756-60.
23. el-Hag A, Clark RA: Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 1987;139:2406-2413.
24. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic t lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985;134:230-4.
25. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of herceptest in determining her-2/neu status of breast cancers using the United States food and drug administration-approved scoring system. J Clin Oncol. 1999;17:1983-7.
26. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17:2411-8.
27. Shimizu C, Ando M, Kouno T, Katsumata N, Fujiwara Y. Current trends and controversies over pre-operative chemotherapy forwomen with operable breast cancer. Jpn J Clin Oncol. 2007;37:1-8.
28. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004;10:3249-61.
29. Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, et al. Prognostic value of estrogen receptor and ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology. 2010;79:255-61.
30. Lee J, ImYH, Lee SH, Cho EY, ChoiYL, KoYH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol. 2008;61:569-77.
31. Schneeweiss A, Katretchko J, Sinn HP, Unnebrink K, Rudlowski C, Geberth M, et al. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs. 2004;15:127-35.
32. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116:53-68.
33. Margeli M, Cirauqui B, Castella E, Tapia G, Costa C, Gimenez- Capitan A, et al. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS ONE. 2010;5:e9499.
34. Bain B, Seed M, Godsland I. Normal values for peripheral blood white cell counts in women of four different ethnic origins. J Clin Pathol. 1984;37:188-93.
35. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-44.
36. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420: 860-7.
37. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87: 504-8.
38. Wu Y, Zhao Q, Peng C, Sun L, Li XF, Kuang DM. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol. 2011;225:438-47.
39. Coussens LM, Tinkle CL, Hanahan D, Werb Z. Mmp-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481-90.
40. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-7.
41. Ulich TR, del Castillo J, Keys M, Granger GA, Ni RX. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol. 1987;139: 3406-15.
42. Ulich TR, del Castillo J, Guo KZ. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood. 1989;73:108-10.
43. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation lc00-03. Eur J Cancer. 2009;45: 1950-8.